Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load
Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups.
대표청구항▼
1. A balloon catheter for delivering a therapeutic agent to a blood vessel while the balloon catheter is deployed at a target site of the blood vessel, the balloon catheter comprising: an elongate member having a lumen and a distal end,an expandable balloon attached to the distal end of the elongate
1. A balloon catheter for delivering a therapeutic agent to a blood vessel while the balloon catheter is deployed at a target site of the blood vessel, the balloon catheter comprising: an elongate member having a lumen and a distal end,an expandable balloon attached to the distal end of the elongate member and in fluidic communication with the lumen; anda coating layer overlying an exterior surface of the expandable balloon, wherein:the coating layer comprises a total drug load of a hydrophobic therapeutic agent and a combination of additives comprising a first additive and a second additive;the hydrophobic therapeutic agent is one of paclitaxel, rapamycin, or combinations thereof;the first additive is one of PEG sorbitan monolaurates, PEG sorbitan monooleates, or combinations thereof; andthe second additive is one of sorbitol, sorbitan, xylitol, gluconolactone, lactobionic acid, or combinations thereof. 2. The balloon catheter of claim 1, wherein the hydrophobic therapeutic agent is paclitaxel. 3. The balloon catheter of claim 1, wherein the hydrophobic therapeutic agent is rapamycin. 4. The balloon catheter of claim 1, wherein the hydrophobic therapeutic agent is uniformly distributed in the coating layer. 5. The balloon catheter of claim 1, wherein the total drug load of the hydrophobic therapeutic agent is from 1 μg to 20 μg per square millimeter of the expandable balloon. 6. The balloon catheter of claim 1, wherein the total drug load of the hydrophobic therapeutic agent is from 2.5 μg to 6 μg per square millimeter of the expandable balloon. 7. The balloon catheter of claim 1, wherein the first additive is a PEG sorbitan monolaurate. 8. The balloon catheter of claim 7, wherein the PEG sorbitan monolaurate is PEG-20 sorbitan monolaurate. 9. The balloon catheter of claim 1, wherein the first additive is a PEG sorbitan monooleate. 10. The balloon catheter of claim 9, wherein the PEG sorbitan monooleate is PEG-20 sorbitan monooleate. 11. The balloon catheter of claim 1, wherein the first additive is one of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, or combinations thereof. 12. The balloon catheter of claim 1, wherein the second additive is one of sorbitol, gluconolactone, or combinations thereof. 13. The balloon catheter of claim 1, wherein the second additive is sorbitol. 14. The balloon catheter of claim 1, wherein the second additive is gluconolactone. 15. The balloon catheter of claim 1, wherein the ratio by weight of the combination of additives in the coating layer to the hydrophobic therapeutic agent in the coating layer is about 10 to 0.5. 16. The balloon catheter of claim 1, wherein: the coating layer consists essentially of the hydrophobic therapeutic agent, the first additive, and the second additive;the hydrophobic therapeutic agent is paclitaxel;the first additive is one of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, or combinations thereof; andthe second additive is one of sorbitol, gluconolactone, or combinations thereof. 17. The balloon catheter of claim 1, wherein: the coating layer consists essentially of the hydrophobic therapeutic agent, the first additive, and the second additive;the hydrophobic therapeutic agent is paclitaxel;the first additive is PEG-20 sorbitan monolaurate; andthe second additive is sorbitol. 18. The balloon catheter of claim 1, wherein: the coating layer consists essentially of the hydrophobic therapeutic agent, the first additive, and the second additive;the hydrophobic therapeutic agent is paclitaxel;the second additive is gluconolactone; andthe total drug load of the hydrophobic therapeutic agent is from 2 μg to 6 μg per square millimeter of the expandable balloon. 19. The balloon catheter of claim 1, wherein the coating layer has a thickness of from about 0.1 μm to 15 μm. 20. A balloon catheter for delivering a therapeutic agent to a blood vessel while the balloon catheter is deployed at a target site of the blood vessel, the balloon catheter comprising: an elongate member having a lumen and a distal end,an expandable balloon attached to the distal end of the elongate member and in fluid communication with the lumen; anda coating layer overlying an exterior surface of the expandable balloon, wherein: the coating layer comprises a total drug load of a hydrophobic therapeutic agent and a combination of additives comprising a first additive and a second additive;the total drug load of the hydrophobic therapeutic agent is from 2.5 μg to 6 μg per square millimeter of the expandable balloon;the hydrophobic therapeutic agent is one of paclitaxel, rapamycin, or combinations thereof;the first additive is one of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, or combinations thereof;the second additive is one of sorbitol, gluconolactone, or combinations thereof; andthe ratio by weight of the combination of additives in the coating layer to the hydrophobic therapeutic agent in the coating layer is about 10 to 0.5.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (238)
Caufield Craig E. (Princeton Junction NJ) Grinfeld Alexander A. (Princeton Junction NJ), 42-Epi-rapamycin and pharmaceutical compositions thereof.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Daniel Castro ; Steven Wu ; Kevin L. Woolbright ; Kurt W. Scheinpflug ; Syed F. A. Hossainy ; Li Chen, Apparatus and method for depositing a coating onto a surface of a prosthesis.
Slepian Marvin J. (Cleveland Heights OH) Schindler Anton (Durham NC), Biodegradable polymeric endoluminal sealing process, apparatus and polymeric product for use therein.
Molnar-Kimber Katherine L. (Glenside PA) Ocain Timothy D. (Waltham MA) Vernon Steven K. (Havertown PA) Huang John J. (San Carlos CA), Biotin esters of rapamycin.
Solomon Donald D. (Spring Valley OH) Taller Robert A. (Centerville OH) Williamitis Victor A. (Dayton OH), Blood compatible, lubricious article and composition and method therefor.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Kao Wenling (Paoli PA) Skotnicki Jerauld S. (Allentown NJ) Abou-Gharbia Magid A. (Glen Mills PA) Palmer Yvette L. (Newtown PA), Carbamates of rapamycin.
Skotnicki Jerauld S. (Allentown NJ) Palmer Yvette L. (Newtown PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapaycin.
Bacher Peter (Nurnberg DEX) Walenga Jeanine M. (Lombard IL), Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
Ragheb, Anthony O.; Bates, Brian L.; Fearnot, Neal E.; Kozma, Thomas G.; Voorhees, III, William D.; Gershlick, Anthony H., Coated implantable medical device.
Amundson Rodney R. (Lindstrom MN) Hull Vincent W. (Ham Lake MN) Dror Michael (Edina MN) Schwartz Robert S. (Rochester MN), Drug delivery balloon catheter with line of weakness.
Fitzhugh,Anthony L.; Cafferata,Robert; Keefer,Larry K., Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use.
Reiley Mark A. ; Scholten Arie ; Talmadge Karen D., Inflatable device for use in surgical protocols relating to treatment of fractured or diseased bones.
Armstrong Jay J. (Bensalem PA) Sehgal Surendra N. (Princeton NJ), Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements.
Bucay-Couto, Weenna; Li, Jamie (Jianmin), Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface.
Skotnicki Jerauld S. (Allentown NJ) Failli Amedeo A. (Princeton Junction NJ) Steffan Robert J. (Langhorne NJ) Kearney Robert M. (Lawrenceville NJ), Macrocyclic immunomodulators.
Hostettler Fritz ; Rhum David ; Forman Michael R. ; Helmus Michael N. ; Ding Ni, Medical device coated with interpenetrating network of hydrogel polymers.
Rosen Gerald M. ; Herzog ; Jr. William R. ; Pou Sovitj, Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosy.
Fan You-Ling (East Brunswick NJ) Marlin Lawrence (Bridgewater NJ) Sahatjian Ronald A. (Lexington MA) Schultz Steven A. (Northboro MA), Medical device with lubricious coating.
Amundson Rodney R. (Lindstrom MN) Hull Vincent W. (Ham Lake MN) Dror Michael (Edina MN) Schwartz Robert S. (Rochester MN), Method for making a drug delivery balloon catheter.
Zhong Sheng-Ping (Farum DKX), Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with s.
Kinsella James L. (Baltimore MD) Sollott Steven J. (Baltimore MD), Method of treating atherosclerosis or restenosis using microtubule stabilizing agent.
Wang, Jeffrey; Malinoff, Harrison; Wang, Lixiao; Barry, Christopher M.; Wahr, Dennis W.; Naisbitt, Scott R., Methods and apparatuses for coating balloon catheters.
Conway Anthony J. (Chatfield MN) Conway Philip J. (Chatfield MN) Fryar ; Jr. Richard D. (Rochester MN), Microcidal agent releasing catheter with balloon.
Roorda,Wouter E.; Ding,Ni; Pacetti,Stephen D.; Michal,Eugene T.; Shah,Ashok A.; Hossainy,Syed F. A., Polyacrylates coatings for implantable medical devices.
Failli Amedeo (Princeton Junction NJ) Kao Wenling (Paoli PA) Steffan Robert J. (Langhorne PA) Vogel Robert L. (Stratford NJ), Rapamycin 42-sulfonates and 42-(N-carbalkoxy) sulfamates useful as immunosuppressive agents.
Failli Amedeo A. (Princeton Junction NJ) Kao Wenling (Paoli PA) Steffan Robert J. (Langhorne PA) Vogel Robert L. (Stratford NJ), Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents.
Sehgal Surendra N. (Dollard des Ormeaux CA) Blazekovic Teodora M. (Mount Royal CA) Vezina Claude (Deux-Montagnes CA), Rapamycin and process of preparation.
Harrison Maureen M. (St. Albans VT) Ofslager Christian L. (Plattsburgh NY) Waranis Robert P. (Chazy NY) Leonard Thomas W. (Wilmington NC), Rapamycin formulations for oral administration.
Failli Amedeo A. (Princeton Junction NJ) Steffan Robert J. (Langhorne PA) Caufield Craig E. (Princeton Junction NJ) Hu David C. (Langhorne PA) Grinfeld Alexander A. (Princeton Junction NJ), Rapamycin oximes.
Failli Amedeo A. (Princeton Junction NJ) Steffan Robert J. (Langhorne PA) Caufield Craig E. (Princeton Junction NJ) Hu David C. (Langhorne PA) Grinfeld Alexander A. (Princeton Junction NJ), Rapamycin oximes.
Kao Wenling (Paoli PA) Vogel Robert L. (Stratford NJ) Abou-Gharbia Magid A. (Glen Mills PA) Caufield Craig E. (Princeton Junction NJ), Rapamycin oximes and hydrazones.
Roorda,Wouter E.; Hossainy,Syed F. A.; Ding,Ni; Tang,Fuh Wei; Pacetti,Stephen D., Rate limiting barriers for implantable devices and methods for fabrication thereof.
Gregory T. Sydney ; Russ Seiber ; Arthur R. Madenjian ; Annette Belovi, Selective coating of a balloon catheter with lubricious material for stent deployment.
Sydney Gregory T. ; Seiber Russ ; Madenjian Arthur R. ; Belovi Annette, Selective coating of a balloon catheter with lubricious material for stent deployment.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Hostettler Fritz ; Rhum David ; Forman Michael R. ; Helmus Michael N. ; Ding Ni, Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a pol.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Fearnot Neal E. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees ; III William D. (West Lafayette IN), Thrombolytic treated intravascular medical device.
Nilsson Bo (Helsingborg SEX) Kalland Terje (Lddekpinge SEX) Termander Birgitta (Helsingborg SEX), Use of Linomide to increase hemopoietic cell precursors.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.